In 1986, Young helped found the Bridge School, an educational organization for children with severe verbal and physical disabilities, and its annual supporting Bridge School Benefit concerts, together with his wife Pegi. Nicolas Hamilton, a British racing driver competing in BTCC. He is the half-brother of Formula 1 driver Lewis Hamilton. Geri Jewell, who had a regular role in the prime-time series The Facts of Life. Josh Blue, winner of the fourth season of NBCs Last Comic Standing, whose act revolves around his CP. Blue was also on the 2004 U.S. Paralympic soccer team. Jason Benetti, play-by-play broadcaster for ESPN, Fox Sports, Westwood One, and Time Warner covering football, baseball, lacrosse, hockey, and basketball. Since 2016, he is also the television play-by-play announcer for Chicago White Sox home games. Jack Carroll, British comedian and runner-up in the seventh season of Britains Got Talent. Abbey Curran, an American beauty queen who represented Iowa at Miss USA 2008 and was the first contestant with a disability to compete. Francesca Martinez, British stand-up comedian and actress. Evan OHanlon, Australian Paralympian, the fastest athlete with cerebral palsy in the world. Arun Shouries son Aditya, about whom he has written a book Does He Know a Mothers Heart
Maysoon Zayid, the self-described "Palestinian Muslim virgin with cerebral palsy, from New Jersey", who is an actress, stand-up comedian, and activist. Zayid has been a resident of Cliffside Park, New Jersey. She is considered one of Americas first Muslim women comedians and the first person ever to perform standup in Palestine and Jordan.
Uridine triacetate (INN), formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine used:

in the treatment of hereditary orotic aciduria (brand name Xuriden  ZOOR-ə-den);
to treat people following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015. References
External links
"Uridine triacetate". Drug Information Portal. U.S. National Library of Medicine.